What I'd do with $100M to maximally disrupt healthcare

Structure. Two-instrument bet: a $20M direct research raise into the platform labs, plus a separate tiered challenge prize of $1M–$100M paid to the first team(s) to re-awaken a mouse after cryopreservation biostasis (independently verified, neurologically intact). The two instruments are deliberately decoupled — the research raise progresses the field even if no team claims the prize, and the prize remains claimable by groups outside the funded labs.

Thesis. Whole-organ vitrification has been demonstrated — Fahy et al. showed a rabbit kidney could be vitrified, rewarmed, and transplanted with sustained life support⁴. No team has yet done the same with a whole mammal. The team that does unlocks reversible biostasis: a foundational platform technology with downstream applications in organ banking ($20B+ annual transplant market today, supply-constrained), trauma medicine, deep-space biology, and indefinite life-extension optionality.

Rationale — direct research raise ($20M). Prizes only work when the underlying science is close enough that a reasonable team can attempt the goal. Biostasis isn't there yet. The $20M funds the foundational pre-prize science: high-throughput cryoprotectant screening, vitrification protocols at organism scale, blood-substitute perfusion, controlled rewarming hardware, and neurological viability assays. Direct funding bypasses the grant-cycle bottleneck and lets 2–4 competing labs work in parallel on shared infrastructure, with open-data deliverables. Without this base layer, the prize has no plausible claimant for a decade.

Rationale — challenge prize ($1M–$100M tiered). Once the science is within reach, a tiered prize attracts >$1B in private speculative R&D from competing labs — the XPRIZE multiplier on the original Ansari prize was ~10×⁵. Tiering ($1M for partial milestones, $100M for full reversible whole-mouse biostasis) keeps capital efficient: small payouts validate intermediate progress, the headline figure forces a global race. The prize itself is escrowed and paid only on independent verification. Downside is bounded; upside is a new industry. This is the same Z-PRIZE structure I'm already actively seeking funders for.

Structure. Two-instrument bet: a $2M direct research raise to design and run a flagship combination-therapy lifespan study in-house, plus a separate tiered challenge prize of $1M–$100M paid to the first team(s) to break the mouse lifespan record reproducibly (independent replication mandatory).

Thesis. The Interventions Testing Program has identified ~10 monotherapies that extend mouse median lifespan by 10–25%⁶. No one had rigorously tested combinations until LEVF.org (Longevity Escape Velocity Foundation, Aubrey de Grey) launched the Robust Mouse Rejuvenation programme⁷. López-Otín's 2023 hallmarks framework predicts that hitting multiple hallmarks in parallel should produce supra-additive effects¹ — but the combinatorial space (10 monotherapies → 1,023 non-empty subsets) is too large for any single lab to explore at scale.

Prior art — LEVF RMR1 and RMR2. RMR1 (n≈1,000 mice, started 2023, completed 2026) combined four interventions in middle-aged mice: rapamycin, navitoclax (senolytic), AAV-mTERT gene therapy, and heterochronic hematopoietic stem cell transplantation^7,8. The result was a "qualified win" — additive (not yet synergistic) benefit, modest magnitude (~4 months extension), and a clean rectangularisation of the survival curve⁹. RMR2 (n≈2,000 mice, ~$3.5M, 20 treatment groups) scales to 8 interventions with rapamycin as a universal baseline, targeting the LEVF-defined Robust Mouse Rejuvenation benchmark: ≥12 months extension of both mean and maximum lifespan in a strain with ≥30-month historic mean, started no earlier than 18 months of age⁷. LEVF has done more to translate the combination hypothesis into hard data than any other group, and any portfolio in this space should explicitly build on RMR1/RMR2 rather than restart from zero.

Rationale — direct research raise ($2M). Funds a flagship combination study built directly on the LEVF RMR pipeline — either co-funding RMR2 endpoints, a third arm (RMR3-equivalent), or a parallel HET3-strain replication to provide direct comparability with NIA ITP data⁶. Pre-registered protocol, public-by-default data release. Three reasons direct funding is necessary alongside the prize: (i) it produces a canonical reference protocol every external claimant can be benchmarked against, removing the methodological ambiguity that has plagued lifespan claims for decades; (ii) it builds the independent replication arm needed to validate any prize claim — the prize is uncollectable without it; (iii) it generates publishable IP and a translatable human protocol regardless of whether the headline prize is ever paid out.

Rationale — challenge prize ($1M–$100M tiered). Compresses years of fragmented academic effort into a 24-month sprint. Tiering rewards graded outcomes — e.g. $1M for the first reproducible +25% median lifespan extension, scaling up to $100M for ≥+100%. Any team that demonstrably exceeds the rapamycin-as-monotherapy benchmark wins on the lower tiers; only a paradigm-shifting result claims the top tier. The judging registry funded by the research raise (above) becomes the canonical benchmark for the field, so even unsuccessful attempts contribute publishable data.

Thesis. Horvath's epigenetic clock¹⁰ and Levine's GrimAge¹¹ measure systemic aging but tell you nothing organ-specific. Tian et al. (2023) and Oh, Wyss-Coray et al. (2023) have now shown organs age at heterogeneous rates and that organ-specific aging predicts disease 5–15 years before clinical presentation^3,12. Whoever owns the canonical 82-organ measurement framework owns the diagnostic layer of an entire industry — and the only credible endpoint stack for organ-rejuvenation prizes G–L below.

What a Zolman Clock actually is. Each Zolman Clock combines all possible modalities spanning the clinically viable subsets of (1) imaging, (2) devices, (3) biosamples and (4) functional performance — the only way to irrefutably attempt to prove age quantification and reversal. Any single-modality clock (DNA methylation alone, MRI alone, proteomics alone) can be gamed, confounded, or invalidated by a more comprehensive measurement; a multi-modal composite cannot. This is the methodological standard the G–L prizes pay against.

Leverage. Phase 1 ($2M) uses existing UK Biobank, Oxford-MRI, and biofluid datasets — no new patient acquisition cost. Phase 2 ($10M+) builds the prospective Organ Age biobank. Defensibility comes from the dataset, not the algorithm — same moat as 23andMe at 100× the clinical relevance.

Thesis. GLP-1s solved fat loss but accelerate sarcopenia — 25–40% of weight lost on semaglutide/tirzepatide is lean mass¹³. Sarcopenia is the proximate driver of frailty, falls, and ~$50B/year in direct US healthcare cost. The mirror-image product to Ozempic — a weekly injectable that selectively grows muscle — is the largest unfilled gap in metabolic medicine. Follistatin and myostatin-inhibitor biology has shown muscle-mass increases of 10–20% in early human work¹⁴. A weekly injectable bypasses gene-therapy regulatory complexity and gives a titratable, reversible product.

Leverage. $2M buys a fully-powered first-in-human safety and pharmacodynamics study. A successful Phase 1 readout unlocks a Series A at 5–10× markup against an addressable market that combines aging, post-bariatric, post-GLP-1, and oncology cachexia populations — easily a $20B+ TAM.

Thesis. N-of-1 trials with rigorous pre/post organ-clock measurement and peer-reviewed publication are the fastest legal route to demonstrating multi-organ age reversal in humans. Each well-documented case becomes a published case report — the same evidence base that built modern immunotherapy.

Leverage. Self-funding through high-net-worth clients seeking access. Each engagement is cash-flow positive while generating publishable data and protocol refinements. Effectively a paid Phase 0 — clients absorb cost, the field absorbs evidence.

Thesis. Lu, Sinclair et al. (Nature 2020) showed three Yamanaka factors — Oct4, Sox2, Klf4 — restore youthful epigenetic state and reverse vision loss in mice¹⁵. Ocampo et al. (Cell 2016) showed partial reprogramming extends lifespan in progeroid mice¹⁶. The translational gap is safety data and human protocol design — both addressable with $2M of focused publication and regulatory groundwork.

Leverage. Altos Labs raised $3B on partial reprogramming. Independent, well-cited publications from a clinician-scientist position create the regulatory and ethical scaffolding the entire field needs and currently lacks.

Endpoint stack. MRI + ultrasound + blood proteomics + ECG + max heart rate + functional performance — 25% combined reversal on the cardiac Zolman Clock.

Rationale. Cardiovascular disease is still the #1 global killer¹⁷. Cardiac age is already measurable via MRI, max heart rate, and proteomic clocks¹². The first team to push a 70-year-old heart's biological age back to 60 wins the prize and a CV-rejuvenation IP estate worth multiples of $10M.

Endpoint stack. Structural and functional MRI + plasma proteomic brain clock + cognitive performance battery — 25% combined reversal on the brain Zolman Clock.

Rationale. Alzheimer's burden alone is projected at $1T/year by 2050. Brain age via MRI is now well-validated³; combined with plasma proteomic clocks and cognitive performance batteries, an objective rejuvenation endpoint is tractable. Wins here unlock the largest single therapeutic market in medicine.

Endpoint stack. High-res MRI + lung ultrasound + spirometry/wearable devices + breath proteomics + blood + performance (e.g. 6MWT) — 25% combined reversal on the lung Zolman Clock.

Rationale. COPD and IPF are individually $30B+ markets with near-zero reversal therapies. A single validated rejuvenation protocol would dominate two stagnant therapeutic categories.

Endpoint stack. Renal MRI + ultrasound + blood (eGFR, cystatin C, proteomics) — 25% combined reversal on the kidney Zolman Clock.

Rationale. CKD affects 850M people globally; dialysis is the single most expensive line item in Medicare. Fahy's vitrified-kidney work⁴ shows the organ tolerates extreme intervention — rejuvenation is downstream.

Endpoint stack. Thymic MRI volumetry + immune-cell flow cytometry + plasma proteomics — 25% combined reversal on the thymus Zolman Clock.

Rationale. The thymus involutes from puberty onward — its decline drives immunosenescence, which drives ~all age-related cancer and infection mortality. Fahy's TRIIM trial (2019) showed thymic regrowth and a 2.5-year epigenetic-age reversal in 9 men¹⁸. The highest leverage organ in the body per dollar spent.

Endpoint stack. MRI + ultrasound + blood (ALT/AST, ELF, proteomics, ferritin/transferrin saturation, hsCRP) — 25% combined reversal on the liver Zolman Clock.

Rationale. NAFLD/MASH affects 30%+ of adults globally with no curative therapy — but this prize deliberately targets intrinsic liver aging, not just steatosis. Even with a perfect MRI-PDFF, a non-fibrotic elastography reading, and normal liver enzymes, the liver still accumulates age-related decline across inflammatory tone (hsCRP, IL-6), fibrotic propensity (ELF score, PIIINP), iron handling (ferritin, transferrin saturation — iron overload is a known accelerator of hepatic and systemic aging), proteomic clock signal, and functional reserve. A 25% combined reversal on the liver Zolman Clock therefore captures rejuvenation even in metabolically clean patients — the population the longevity market most plausibly buys this product for first. Secondary upside: an immediate $50B+ NAFLD/MASH market.

Thesis. All of the above generates evidence. None of it reaches patients without a dedicated translation and access infrastructure. Longevity School is the existing education channel — 50+ hours of AGREE2/IPDAS-compliant protocol training. The new build is a dedicated global translation team: protocol localisation into the top 10 medical languages, regulatory liaison in priority jurisdictions (UK, US, EU, UAE, Singapore, Japan, India, Brazil), and a credentialed-clinician access network so any validated protocol from projects A–L reaches practising doctors inside 12 months of publication.

Leverage. Evidence without a distribution channel is academic exhaust. A dedicated translation team converts every prize claim and every published case report into a global, clinician-deliverable standard of care — and protects the foundation's mission from being captured by any single national regulator or commercial actor.